MAS Drug Discovery and Clinical Development 2020

This MAS is aimed at professionals from academia, the pharmaceutical industry, biotechnology sector, and international organizations who wish to gain an in-depth understanding of drugs and medical devices research and development.

Information

Period

August 2020 - June 2021
60 ECTS credits
280 Teaching hours
Every 2 years

Language

English

Format

On-site

Contact

Location

Geneva

Registration

Registration deadline

31 July 2020
Modules can be followed individually

Fees:

CHF 13’000.- for the Master
CHF 1’500.- for individual modules

Contribution to the SDGs

Goal 3: Ensure healthy lives and promote well-being for all at all ages Goal 9: Build resilient infrastructure, promote inclusive and sustainable industrialization and foster innovation Goal 16: Promote peaceful and inclusive societies for sustainable development

Objectives

  • Provide essential business knowledge of drug and medical devices in clinical research and development
  • Give health professionals the tools to comply with the highest scientific and ethical standards in clinical research
  • Empower physicians and health scientists to lead clinical trials within hospitals, pharmaceutical and biotechnology companies
  • Enable health professionals to gain a strategic vision of clinical development and navigate the complexities of bringing new medicinal products to the global market

Audience

Medical doctor, biologist, pharmacist, nurse, biochemist and other professional involved or wishing to gain skills and knowledge, in the field of drug discovery and development

Learning outcomes

  • Understand the stakes, challenges and opportunities of drug discovery and development
  • Master the fundamental scientific and ethical principles of drug discovery and development
  • Gain knowledge of Good Clinical Practices (GCP) and of clinical research regulations in Switzerland, Europe and the United States
  • Learn how to navigate clinical trial authorization and marketing authorization processes
  • Master effective planning and management for clinical trials
  • Successfully manage partnerships with pharmaceutical and biotechnology partners
  • Understand the issues related to research subject protection
  • Understand and take up the challenges of new technologies and personalized medicine

Programme

12 modules:

  • Introduction to Clinical Development: Challenges and Prospects
  • Principles and Methods of Clinical Research
  • Ethical and Legal Aspects
  • Preclinical Pharmacology, Toxicology and Clinical Pharmacology
  • Safety Management and Drug Development
  • Medical Statistics and Trial Methodologies
  • Clinical Trials Set-up and Conduct part 1
  • Clinical Trials Set-up and Conduct part 2
  • Regulatory Considerations in Drug Development
  • Clinical Trials Close-out and Reporting
  • Audits and Inspections
  • New Perspectives, Personalized Medicine and New Therapeutics

Thesis

Director(s)

Prof. Jules DESMEULES, Faculty of Medicine, Faculty of Science, University of Geneva and Dr. François CURTIN, GeNeuro

Coordinator(s)

Dr François CURTIN, Faculty of Medicine, University of Geneva, Dr Catherine DELOCHE, Solid Drug Development et Dr Françoise LASCOMBES, External consultant

Accreditation

This programme is accredited by Swissethics, Swiss Association of Pharmaceutical Professionals, Swiss Society of Clinical Pharmacology and Toxicology, Swiss Institute for postgraduate and continuous medical education
The Mediator® scandal: A case of shared responsibilities
Recherche clinique sur la COVID-19

Pedagogical method

Lectures, interactive seminars, workshops, vocational training. Teaching is in English or in French.

Admission criteria

  • Title of physician
  • Or master's or bachelor's degree in Life Science or title deemed equivalent
  • Or Bachelor's degree from a Swiss University of Applied Science plus a minimum of 1 year professionnal experience in clinical development
  • Good understanding of both French (knowledge equivalent to B2 Level) and English (knowledge equivalent to the Cambridge First Certificate)

Steering committee

Prof. Cem Gabay, Dean of the Faculty of Medicine, University of Geneva
Prof. Arnaud Perrier, Medical Director, University Hospitals of Geneva
Prof. Gerrit Borchard, Head of Biopharmaceutics, Section of Pharmaceutical Sciences, Faculty of Science, University of Geneva
Dr Angèle Gayet-Ageron, CC, Lecturer, Head of the Methodological Support Unit, Clinical Research Centre (CRC), University Hospitals of Geneva, Faculty of Medecine, University of Geneva
Prof. Bernard Hirschel, President, Cantonal Commission on Human Research Ethics, Canton of Geneva
Prof. Samia Hurst, Director, Institute of Ethics, History and Humanities (iEH2), Faculty of Medicine, University of Geneva
Prof. Jérôme Pugin, Vice-Dean of the Faculty of Medicine and President of the Clinical Research Center (CRC), University Hospitals of Geneva, Faculty of Medicine, University of Geneva

Comité scientifique

Dr Emilie Alirol, Project Leader, Global Antibiotics Research and Development Partnership (GARDP), Drugs for Neglected Diseases initiative (DNDi)
Dr Vanya Beltrami, Vice-President, Head of Manufacturing, Anergis, Lausanne
Dr Jocelyne Chabert, Clinical Research Associate, Clinical Research Centre (CRC), University Hospitals of Geneva, Faculty of Medicine, University of Geneva
Dr Francois Curtin, PD, Medical Director Personalised Health Programmes, Swiss Federal Institute of Technology in Zürich (ETH Zürich) & Lecturer at Hospitals of Geneva (UNIGE)
Dr Patricia Delaite, Medical Director, Geneva
Dr Catherine Deloche, Chief Operating Officer, Solid Drug Development, Geneva
Prof. Philippe Ducor, Faculty of Law, University of Geneva
Prof. Marc Froissart, Chief Medical Director of the Clinical Research (CRC), CHUV-UNIL, Lausanne
Dr Angèle Gayet-Ageron, CC, Lecturer, Head of the Methodological Support Unit, Clinical Research Centre (CRC), University Hospitals of Geneva, Faculty of Medecine, University of Geneva
Dr Françoise Lascombes, External Consultant
Prof. Hervé Porchet, Pharmaceutical consultant
Dr Victoria Rollason, PharmD, Division of Clinical Pharmacology and Toxicology, University Hospitals of Geneva and Faculty of Medicine, University of Geneva
Dr Gabriele Ackermann, Chief Scientific Officer ad interim, Therapeutic Area Head Cardiovascular, Renal & Metabolism Therapeutic Area Head Respiratory, Novartis Pharma Switzerland

Number of participants

Le nombre de participants est adapté à la pédagogie choisie.

Contribution to the SDGs

Goal 3: Ensure healthy lives and promote well-being for all at all ages Goal 9: Build resilient infrastructure, promote inclusive and sustainable industrialization and foster innovation Goal 16: Promote peaceful and inclusive societies for sustainable development

Les termes utilisés pour désigner des personnes sont pris au sens générique; ils ont à la fois la valeur d'un masculin et d'un féminin.